Comparison of acute non-haemolytic transfusion reactions in female and male patients receiving female or male blood components.
To study the relationship between antibodies detected in patients' and/or donors' sera and the clinical features of acute non-haemolytic transfusion reactions (ANHTRs), and to determine any gender-related difference. ANHTRs range from urticaria to transfusion-related acute lung injury (TRALI). Antibodies to human leukocyte antigen (HLA), granulocytes, platelets, and/or plasma proteins are implicated in some of the ANHTRs. A higher antibody positivity is expected for females than for males. A comparative study of ANHTRs for antibody positivity and their clinical features between females and males for both patients and donors is helpful for characterizing ANHTRs including TRALI more clearly, but such studies are few and outdated. Two hundred and twenty-three ANHTR cases reported by 45 hospitals between October 2000 and July 2005 were analysed. The patients and 196 donors of suspect blood products were screened for antibodies to HLA Class I, HLA Class II, granulocytes, and platelets. The patients were also screened for anti-plasma protein antibodies. The types and severity of ANHTR did not differ significantly between female and male patients. The frequency of the anti-HLA antibodies, but not that of the non-HLA antibodies, was significantly higher in females. Non-HLA antibodies were significantly associated with severe reactions in females. All the TRALI cases had predisposing risk factors for acute lung injury, and 60% of the cases showed anti-leucocyte antibodies. Although the anti-HLA antibodies were detected more frequently in females than males, no significant association of ANHTRs including TRALI with gender, not only for patients, but also for donors, could be shown in this study.
Imoto
S
S
Hyogo Red Cross Blood Center, Kobe, Japan. imoto@hyogo.bc.jrc.or.jp
Araki
N
N
Shimada
E
E
Saigo
K
K
Nishimura
K
K
Nose
Y
Y
Bouike
Y
Y
Hashimoto
M
M
Mito
H
H
Okazaki
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D016824:Antigens, Human Platelet / Q000276:immunology; D016913:Blood Component Transfusion / Q000009:adverse effects*; D001782:Blood Donors; D001798:Blood Proteins / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007518:Isoantibodies / Q000097:blood; D008297:Male; D008875:Middle Aged; D010949:Plasma; D012128:Respiratory Distress Syndrome / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D012307:Risk Factors; D012737:Sex Factors; D014581:Urticaria / Q000453:epidemiology / Q000209:etiology / Q000276:immunology
D016824:Antigens, Human Platelet; D001798:Blood Proteins; D006680:HLA Antigens; D007518:Isoantibodies